Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2018 1
2019 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Direct versus sequential immunoglobulin switch in allergy and antiviral responses.
Svirshchevskaya E, Fattakhova G, Khlgatian S, Chudakov D, Kashirina E, Ryazantsev D, Kotsareva O, Zavriev S. Svirshchevskaya E, et al. Clin Immunol. 2016 Sep;170:31-8. doi: 10.1016/j.clim.2016.07.022. Epub 2016 Jul 25. Clin Immunol. 2016. PMID: 27471213
The aim of this work was to analyze the distribution of immunoglobulins (Ig) to house dust mite D. farinae and A. alternata fungus in allergic children with primarily established diagnosis and compare it to Epstein-Barr antiviral (EBV) response in the same patients. In all …
The aim of this work was to analyze the distribution of immunoglobulins (Ig) to house dust mite D. farinae and A. alternata fungus in allerg …
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.
Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu Y, Lee DY, O'Connor O, Gee AP, Brenner MK, Heslop HE, Rooney CM. Bollard CM, et al. J Clin Oncol. 2018 Apr 10;36(11):1128-1139. doi: 10.1200/JCO.2017.74.3179. Epub 2018 Jan 9. J Clin Oncol. 2018. PMID: 29315015 Free PMC article.
Materials and Methods In a dose escalation study, eight patients with Epstein Barr virus-positive Hodgkin lymphoma received two to 12 doses of between 2 10(7) and 1.5 10(8) cells/m(2) of DNRII-expressing T cells with specificity for the Epstein Barr virus-derived tu …
Materials and Methods In a dose escalation study, eight patients with Epstein Barr virus-positive Hodgkin lymphoma received two to 12 …
HLA Associations and Risk of Posttransplant Lymphoproliferative Disorder in a Danish Population-Based Cohort.
Vase MØ, Maksten EF, Strandhave C, Søndergaard E, Bendix K, Hamilton-Dutoit S, Andersen C, Møller MB, Sørensen SS, Kampmann J, Eiskjær H, Iversen M, Weinreich ID, Møller B, Jespersen B, d'Amore F. Vase MØ, et al. Transplant Direct. 2015 Aug 11;1(7):e25. doi: 10.1097/TXD.0000000000000534. eCollection 2015 Aug. Transplant Direct. 2015. PMID: 27500227 Free PMC article.
Risk factors for PTLD include T cell-depleting induction therapy and primary infection or reactivation of Epstein-Barr virus. Possible associations between certain HLA types and the risk of developing PTLD have been reported by other investigators; however, results are con …
Risk factors for PTLD include T cell-depleting induction therapy and primary infection or reactivation of Epstein-Barr virus. Possibl …
Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution.
Salas MQ, Climent F, Tapia G, DomingoDomènech E, Mercadal S, Oliveira AC, Aguilera C, Olga G, Moreno Velázquez M, Andrade-Campos M, Encuentra M, Fernández de Sevilla A, Sureda A, Sancho JM, González-Barca E. Salas MQ, et al. Biomarkers. 2020 Feb;25(1):69-75. doi: 10.1080/1354750X.2019.1691656. Epub 2019 Nov 21. Biomarkers. 2020. PMID: 31752540
No significant differences were found in overall survival and progression-free survival (PFS), although there was a trend towards better PFS in CD30-positive patients (p = 0.07). Among 7 patients with Epstein-Barr virus (EBV)-positive-DLBCL, CD30 was expressed in 71%, and …
No significant differences were found in overall survival and progression-free survival (PFS), although there was a trend towards better PFS …